Hims & Hers has acquired a U.S.-based peptide facility in California to enhance its ability to deliver personalized medications and strengthen its domestic supply chain. The acquisition aligns with the company's commitment to meeting the growing demand for personalized healthcare while maintaining high standards of quality, safety, and availability. By integrating this facility into its operations, Hims & Hers aims to improve cost management, ensure consistent supply, and offer greater control over product quality. This move builds on the company’s previous acquisitions of 503A and 503B facilities, furthering its long-term strategy to scale personalized care and maintain operational efficiency within the United States.
The newly acquired facility also expands Hims & Hers’ capabilities in peptide innovation, positioning the company to explore advancements in areas including preventive health, metabolic optimization, cognitive performance, recovery science, and biological resistances. The acquisition, which was finalized in early February, reflects the company's ongoing investment in infrastructure to support the increasing demand for personalized treatments.
